{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-009865","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2021-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.044086+00:00","generated_at":"2026-06-29T23:40:17.332809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year","bullets":["Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).","Non-GAAP diluted EPS $0.80 vs $1.24 prior year; GAAP net income $149M down from $290M.","Positive CHMP opinion for tafasitamab in relapsed/refractory DLBCL; Phase 3 vitiligo trials met endpoints.","Updated 2021 guidance: Jakafi revenue tightened to $2,125-$2,170M; SG&A reduced to $725-$755M.","Retifanlimab BLA received FDA complete response letter; MAA still under EMA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-009865","json":"https://secwatch.observer/filing/0001558370-21-009865.json","markdown":"https://secwatch.observer/filing/0001558370-21-009865.md","text":"https://secwatch.observer/filing/0001558370-21-009865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/0001558370-21-009865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000155837021009865/incy-20210803x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:40:17.332809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}